Tuesday, 10 April 2018

Mylan buys marketing rights to MS treatment from Israel's Mapi Pharma

(Reuters) - Drugmaker Mylan NV is acquiring global marketing rights to an experimental multiple sclerosis treatment from Israel's Mapi Pharma Ltd, the companies said on Tuesday.


No comments:

Post a Comment